Amgen stock price near $342: AMGN heads into earnings after Kyowa Kirin deal exit
Amgen shares fell 0.3% to $341.88 after the company disclosed plans to exit its eczema drug partnership with Kyowa Kirin. Kyowa Kirin will regain full rights to rocatinlimab, with regulatory submission expected in the first half of 2026. Amgen reports earnings Tuesday after market close.
